Christopher R. Cogle, MD

Home Research Research Grants Program Grants Awarded All Grant Recipients Christopher R. Cogle, MD

Grantee: Christopher R. Cogle, MD

IInstitution: University of Florida
Project Title: Defining the Hemangioblast in Tumor Neoangiogenesis
Award: 2003 Samuel Stroum – Pancreatic Cancer Action Network – ASCO Young Investigator Award
Award Period: July 1, 2003 – June 30, 2004
Amount: $35,000
Click here to download Dr. Cogle’s Grant Snapshot (pdf)

Biographical Highlights
After receiving his MD from University of Florida in Gainesville, Dr. Cogle completed a residency in internal medicine and a fellowship in medical oncology at the University of Florida Shands Hospital and Malcolm Randall VA Medical Center. He completed fellowship training in blood and marrow transplantation at Duke University Medical Center in Durham, NC. Early in his career, Dr. Cogle discovered that human blood stem cells make blood vessels in addition to blood, and that cancers co-opt bone marrow to make cancer blood vessels. He has identified critical mechanisms in this interaction and has developed novel methods to block new blood vessel growth within cancer. In 2005 Dr. Cogle was name one of the top ten young U.S. scientists by the British Council.

Project Description
In the developing embryo, both blood cells and blood vessels are formed from a common precursor cell called a hemangioblast. Dr. Cogle has shown that adult blood stem cells act much like hemangioblasts in that they also contribute to new blood vessel development. Given his experience with blood stem cells repairing injured blood vessels, Dr. Cogle hypothesizes that blood stem cells also contribute to blood vessels in cancer. Using mouse models of pancreatic, lung, melanoma and lymphoma, the funded study aims to determine if blood stem cells do in fact contribute to the growth of blood vessels that feed cancers. Plans are to analyze these blood vessels for evidence that they originated from blood stem cells. If so, these cells may represent an excellent target to prevent the uncontrolled growth of pancreatic and breast cancer. This could be done by blocking the ability of blood stem cells to reproduce and migrate to the tumor, therefore stopping new blood vessel growth, starving the cancer of nutrients and stunting its growth.

Dr. Cogle’s laboratory recently found that pancreatic cancer and lung cancer attract bone marrow cells into growing tumors. Some of these bone marrow cells contribute to blood vessels within the cancers. Dr. Cogle also discovered that a certain critical protein is responsible for attracting bone marrow cells to sites of cancer growth. By blocking the protein, the growth of cancers can be stunted.

Lessons Learned
As with all of medicine, nature and science: assume nothing, critically appraise everything (including your own thoughts), be ready to be surprised, a strong sense of urgency is contagious, rarely will curiosity waste time, listen hard because Mother Nature rarely shouts, and most importantly, never lose sight of the big picture – patients with cancer (and their families and friends) are counting on us to make real differences.

Next Steps
Dr. Cogle plans to develop his anti-cancer treatment into a clinical pilot study. He will also begin to investigate other signaling pathways that attract bone marrow cells into cancer environments.

Follow-Up Funding
James & Esther King Biomedical Research Program Grant, Florida Department of Health (07/01/05 – 06/30/09; Amount: $450,000). Define signaling pathways involved in marrow contribution to cancer blood vessels.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved.

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision PromiseSM and Demand Better For Patients. For Survival.SM are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.